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Abstract Recent findings have suggested that the cellular 
proteolytic system plays a major role in the regulation of various 
intra- and extra-cellular signaling. It was previously shown that 
proteolytic treatment of adenylyl cyclase leads to the activation 
of this enzyme. We demonstrate that this activation occurs in an 
adenylyl cyclase isoform-dependent manner. The type II isoform 
was strongly activated (~500%), the type III isoform was 
modestly activated (~30%), and the type V isoform was 
inhibited by trypsin. Activation of type II adenylyl cyclase 
occurred in trypsin dose- and time-dependent manners and was 
blocked by a trypsin inhibitor in a dose-dependent manner. Other 
proteases, such as thrombin and plasminogen, similarly activated 
the type II isoform, but not the others. Our data suggest that 
proteolytic activation is an isoform- and thus cell type-dependent 
mechanism of altering adenylyl cyclase catalytic activity. 
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1. Introduction 
A variety of agents are known to regulate the catalytic 
activity of adenylyl cyclase [1,2]. Many hormones and neuro-
transmitters activate adenylyl cyclase through the cell surface 
receptors and thereby the stimulatory G-protein, Gsa. So-
dium fluoride and guanine nucleotide analogs activate adenyl-
yl cyclase by activating Gsa. Forskolin directly interacts with 
adenylyl cyclase and enhances its catalytic activity. Post-trans-
lational modification of adenylyl cyclase such as phosphoryla-
tion by protein kinase C also enhances cAMP production. 
Changes in the cation concentration, such as Mg and Mn, 
are yet another mechanism of regulating the catalytic activity 
of this enzyme. 
Besides these mechanisms, it has been known that adenylyl 
cyclase is activated by proteolysis. The adenylyl cyclase system 
of rat liver plasma membranes was originally found to be 
stimulated by proteases contained in bacterial collagenase 
preparations [3]. This observation was extended by numerous 
other findings that demonstrated the activation of adenylyl 
cyclase by a variety of proteinases including trypsin, chymo-
trypsin, plasmin, and thrombin [4-6]. However, the effect of 
proteases and the degree of stimulation, as well as the site of 
interaction, were not consistent among studies using different 
tissues and proteases [4-6]. 
Recent molecular cloning studies in the past 5 years re-
vealed that adenylyl cyclase consists of multiple isoforms [2]. 
Although they all share the common structure, i.e., a module 
of six transmembrane spans linked to a large cytoplasmic 
domain that is tandemly repeated, these isoforms have distinct 
amino acid sequences, biochemical properties, and tissue dis-
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tribution. Recent studies have also suggested that the cellular 
proteolytic system plays a major role in the regulation of 
various intra- and extra-cellular signaling, including cAMP 
signaling [7]. In the present work, we use adenylyl cyclase 
isoforms overexpressed in insect cells to show that proteolytic 
activation of adenylyl cyclase is not a common property but 
one that belongs only to certain isoforms of adenylyl cyclase. 
2. Materials and methods 
2.1. Materials 
Proteases (trypsin, plasminogen, and thrombin) and trypsin inhibi-
tor (ovomucoid from chicken egg white) were purchased from Sigma 
(St. Louis, MO). 
2.2. Overexpression of recombinant adenylyl cyclase isoforms 
Overexpression of types II and V adenylyl cyclase in insect cells was 
accomplished with the pBluBac system (Invitrogen, San Diego, CA) 
as previously described [8-10]. For type III adenylyl cyclase, a Bam-
HI-.ff!>idIII cDNA fragment was subcloned into a pBluBacHisB vec-
tor, and a high-titer virus stock solution was prepared as previously 
described [8]. Type II and III adenylyl cyclase cDNA clones were 
kindly provided by Dr. R. Reed (Johns Hopkins University). 
2.3. Insect cell membrane preparations 
Types II, III, and V adenylyl cyclase were overexpressed in High 
Five (H5) insect cells as previously described [8]. In brief, 60 h after 
infection, insect cells were washed twice with ice-cold phosphate-buf-
fered saline and homogenized in a buffer containing 50 mM Tris-HCl 
(pH 8.0), 1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol, and 200 
mM sucrose in the presence or absence of a protease inhibitor mixture 
(10 μg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 50 U of egg 
white trypsin inhibitor, 20 μg/ml L-l-tosylamido-2-phenylethyl chloro-
methyl ketone, 20 μg/ml l-chloro-3-tosylamido-7-amino-2-heptanone, 
and 2 μg/ml aprotinin). Cells were disrupted with a sonicator or Poly-
tron and centrifuged at 500 Xg for 10 min at 4°C. The supernatants 
were further centrifuged at 100000Xg for 30 min at 4°C. The result-
ant pellets were resuspended in the same buffer without EGTA. The 
crude membrane preparations were stored at — 70°C until use. 
2.4. Adenylyl cyclase assay 
Adenylyl cyclase activity was measured as previously described [11]. 
In brief, 4 μg of the crude membrane preparations from insect cells 
overexpressing adenylyl cyclase isoforms was incubated in a buffer 
containing 20 mM Hepes (pH 8.0), 5 mM MgCl2, 0.2 mM EDTA, 
0.2 mM dithiothreitol, 0.1 mM ATP, 0.1 mM cAMP, 1 mM creatine 
phosphate, 8 U/ml creatine phosphokinase, and [32P]aATP (= 1 \xC\l 
assay tube). Trypsin and other proteases were added to the reaction 
mixture when the assay was started. The reaction mixture was incu-
bated for 20 min at 30°C. cAMP was separated by the method of 
Salomon [12]. Protein concentration was determined by the method of 
Bradford [13]. 
3. Results 
3.1. Activation of type II adenylyl cyclase by trypsin 
When the reaction mixture contained trypsin, the forskolin-
stimulated catalytic activity was altered in trypsin concentra-
tion- and adenylyl cyclase isoform-dependent manners (Fig. 
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Fig. 1. Effects of trypsin on type II, III, and V adenylyl cyclase cat-
alytic activity. A: Effects of trypsin on forskolin-stimulated activity. 
B: Effects of trypsin on basal activity. Adenylyl cyclase assays were 
performed in the presence (A) and absence (B) of 100 μΜ forskolin 
with an increasing concentration of trypsin. · , type II adenylyl cy-
clase; ▲ , type III adenylyl cyclase; ■, type V adenylyl cyclase. 
Means ± SEM from 3 to 6 independent assays are shown. *P<0.05; 
**P<0.0f differences form the values without trypsin. In the ab-
sence of trypsin, the forskolin-stimulated activity was 11.4±1.5 
nmol/20 min/mg for type II, 6.24 ± 0.77 nmol/20 min/mg for type 
III, and 25.2 ±2.03 nmol/20 min/mg for type V. The basal activity 
was 1.62 ±0.11 nmol/20 min/mg for type II, 0.27 ±0.02 nmol/20 
min/mg for type III, and 1.38 ±0.24 nmol/20 min/mg for type V. 
1A). At low concentrations (0.1-2 μg/ml), trypsin strongly 
(~500%) activated the type II isoform, modestly (~20%) 
activated the type III isoform, and scarcely activated the 
type V isoform. At high concentrations, trypsin inhibited all 
three isoforms. A similar pattern of alteration was observed 
when assays were performed without forskolin (Fig. IB). 
Thus, the effect of trypsin was biphasic, and the degree of 
activation was dependent upon the isoform of adenylyl cy-
clase. 
3.2. Time-course of the activation of the type II isoform 
The activation of the type II isoform by trypsin was time-
dependent (Fig. 2). As early as 5 min after initiation of the 
reaction, trypsin (2 μg/ml) significantly increased the catalytic 
activity of type II adenylyl cyclase compared with the activity 
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Fig. 2. Effect of trypsin inhibitor on type II adenylyl cyclase activa-
tion by trypsin. Adenylyl cyclase assays were performed in the ab-
sence (·) or presence (o) of trypsin (0.4 μg/ml) with an increasing 
concentration of a trypsin inhibitor (ovomucoid from egg white). 
Means ± SEM from 3 independent assays are shown. *P<0.05 for 
differences between the values with and without trypsin. 
without trypsin. The rate of cAMP production was constant 
in the absence of trypsin for 30 min; however, the rate grad-
ually decreased over 30 min in the presence of trypsin. 
3.3. Effect of trypsin inhibitor 
Stimulation of type II adenylyl cyclase by trypsin was ne-
gated in the presence of a trypsin inhibitor. Ovomucoid from 
chicken egg white, a trypsin inhibitor, in the reaction mixture 
prevented the activation by trypsin in a dose-dependent man-
ner (Fig. 3). 
3.4. Kinetic analysis 
Activation of type II adenylyl cyclase by trypsin was ac-
companied by changes in kinetic parameters. The Vmax value 
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Fig. 3. Time-course of the activation of type II adenylyl cyclase by 
trypsin. Adenylyl cyclase assays were performed in the absence (·) 
or presence (o) of trypsin (2 μg/ml) for the indicated time. Means 
±SEM from 4 independent assays are shown. *P<0.05 for differ-
ences between the values with and without trypsin. 
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Fig. 4. Kinetic analysis (Lineweaver-Burk plot) of the activation of 
type II adenylyl cyclase by trypsin. Four micrograms of crude mem-
branes overexpressing type II adenylyl cyclase were incubated in the 
absence (·) and presence (o) of trypsin (0.4 μg/ml) for 5 min at 
30°C. After 5 min incubation, the reaction was stopped by the addi-
tion of 2 μg of a trypsin inhibitor from egg white. Adenylyl cyclase 
assays were performed in the presence of an increasing concentra-
tion of ATP for 15 min at 30°C. Vm&x: 0.97±0.17 to 1.24±0.24 
nmol/min/mg (n = 3), n.s. Km: 93.7±5.6 to 50.7±4.1 μΜ (η = 3), 
i><0.05 
was increased by 26% while the Km value decreased by 46%, 
although only the latter change was statistically significantly 
(Fig. 4). 
3.5. Effects of plasmin and thrombin 
When plasmin ((M00 μg/ml) and thrombin (0-500 U/ml) 
were part of the reaction mixture, they mimicked the effect of 
trypsin. They altered the forskolin-stimulated catalytic activity 
of adenylyl cyclase in protease concentration- and adenylyl 
cyclase isoform-dependent manners (Fig. 5). At low concen-
trations, these proteases strongly activated the type II isoform 
(500-700%), while the other isoforms were either inhibited or 
unaffected. At high concentrations, the stimulation of type II 
adenylyl cyclase was weak. 
4. Discussion 
Our data show that proteolytic activation of adenylyl cy-
clase occurs in an isoform-dependent manner. In particular, 
the type II isoform was potently activated. Type II adenylyl 
cyclase belongs to a subgroup consisting of types II, IV, and 
VII, which are widely distributed in many, but not all, tissues 
[14-16]. Type III adenylyl cyclase, a major olfactory isoform, 
was poorly activated [17]. Type V adenylyl cyclase, a member 
of the cardiac subgroup, was resistant to proteolytic activa-
tion [18]. The effect of other serine proteases, such as plasmin 
and thrombin, was similar to that of trypsin among these 
isoforms. The fact that proteolytic activation by trypsin oc-
curred only in a subset of adenylyl cyclase isoforms may ex-
plain the inconsistent results in past studies using different 
tissues. Trypsin stimulated adenylyl cyclase from ovarian tis-
sues [5,19] and fibroblasts [20,21] but had no effect on or was 
inhibitory to adenylyl cyclase from liver and erythrocytes 
[4,22]. We now know that each tissue expresses a distinct 
mixture of adenylyl cyclase isoforms. 
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We do not know the exact mechanism that specifically ac-
tivates type II adenylyl cyclase. It may unmask a new catalytic 
site(s) by removing a putative inhibitory domain within this 
enzyme through peptide band hydrolysis. Alternatively, it may 
modify the conformation of this isoform. We and others have 
recently demonstrated that type II adenylyl cyclase catalytic 
activity is sensitive to conformational changes [23,24]. 
The cellular proteolytic system is now known to be involved 
in the regulation of various intra- and extra-cellular signaling 
[7]. The role of proteolysis may vary from the degradation of 
disused proteins to the formation and activation of a specific 
class of enzymes and hormones. A cascaded proteolytic reac-
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Fig. 5. Effects of plasmin and thrombin on adenylyl cyclase iso-
forms (types II, III, and V). A: Effect of plasmin. Adenylyl cyclase 
assays were performed in the presence of 100 μΜ forskolin with an 
increasing concentration of plasmin. Means ± SEM from 3 or 4 in-
dependent assays are shown. *P<0.05; **P<0.01 for differences 
from the values without plasmin. In the absence of plasmin, the for-
skolin-stimulated activity was 15.9 ± 1.9 nmol/20 min/mg for type II, 
6.48 ±0.59 nmol/20 min/mg for type III, and 29.6 ±2.4 nmol/20 
min/mg for type V. B: Effect of thrombin. Adenylyl cyclase assays 
were performed in the presence of 100 μΜ forskolin with an in-
creasing concentration of thrombin. Means ± SEM from 3 or 4 inde-
pendent assays are shown. *P<0.05; **P<0.01 for differences from 
the values without thrombin. In the absence of thrombin, the for-
skolin-stimulated activity was 15.7 ±2.3 nmol/20 min/mg for type II, 
5.97 ±0.62 nmol/20 min/mg for type III, and 32.3 ±1.6 nmol/20 
min/mg for type V. · , type II adenylyl cyclase; ▲, type III adenylyl 
cyclase; ■, type V adenylyl cyclase. 
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tion triggered by extracellular stimuli may also result in the 
control of cell proliferation and differentiation as well as in 
the programmed cell death. The c A M P signaling system is 
known to regulate intracellular proteolytic activity. c A M P 
accelerates the proteolytic processing of proenkephalin to en-
kephalin [25]. c A M P activates elastase in T cells [26]. c A M P 
enhances the transcription of granzyme B, a protease from 
cytotoxic T lymphocytes that is known to play a major role 
in T lymphocyte-mediated apoptosis [27]. c A M P is also 
known as an inducer of apoptosis in certain cell types [28,29]. 
With these recent findings, it may not be surprising that the 
c A M P signaling is regulated through proteolysis. LH-stimu-
lated c A M P production and subsequent steroidogenesis in 
Leydig cells requires proteolysis [30]. ß-agonist-induced acti-
vation of calpain in alveolar epithelial type II cells leads to 
proteolytic activation of cAMP-dependent protein kinase [31]. 
Similar proteolytic activation of protein kinase A is also 
shown in aplasia [32]. Furthermore, regulation of a second 
messenger producing enzyme by the proteolytic system has 
been demonstrated: phospholipase C, a diacyl glycerol-pro-
ducing enzyme, is activated through proteolysis by calpain 
in an agonist-induced manner [33]. Although we do not 
know the exact mechanism of adenylyl cyclase activation 
through proteolysis in vivo, our findings suggest that this 
activation occurs in an isoform-dependent manner and thus 
in selected cell types that express proteolysis-sensitive adenylyl 
cyclase isoforms. Certainly, further studies are needed to elu-
cidate this issue. 
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